Robson, Mark <br/><br/>
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  10 2019 
 - 20-30 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2019.06.023  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Biomarkers, Tumor--genetics<br/>Breast Neoplasms--drug therapy<br/>Capecitabine--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Furans--administration & dosage<br/>Germ-Line Mutation<br/>Humans<br/>International Agencies<br/>Ketones--administration & dosage<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Patient Reported Outcome Measures<br/>Phthalazines--administration & dosage<br/>Piperazines--administration & dosage<br/>Prognosis<br/>Quality of Life<br/>Receptor, ErbB-2--metabolism<br/>Survival Rate<br/>Time-to-Treatment<br/>Vinorelbine--administration & dosage<br/>Young Adult